The Varicella zoster vaccine is made from the Oka/Merck strain of live attenuated varicella virus. PCR can have positive varicella zoster virus. These infections include, among others, various viruses (measles, varicella zoster encephalitis, rubella, enterovirus 71). The characteristic skin lesions of a varicella zoster virus (VZV) infection are called "chickenpox". Cangene also produces pharmaceuticals that treat Hepatitis B and varicella (chickenpox). The usage expanded to include topical treatment of herpes simplex, zoster, and varicella. Shingles is due to a reactivation of varicella zoster virus (VZV) in a person's body. The evidence is more limited for coccidioidomycosis, measles, smallpox, and varicella. The vaccines given were DTaP, Hib, MMR, varicella, and inactivated polio. Adult shingles cases may increase after introduction of varicella vaccine, but evidence is unclear. The varicella vaccine is recommended in many countries. Population-based immunization against varicella is not otherwise practised in the UK. Ninety percent of cases of varicella pneumonia occur in the adult population. Infection late in gestation or immediately following birth is referred to as ""neonatal varicella"". The second dose, if given, provides the additional benefit of improved protection against all varicella.